Among the biological approaches to therapeutics, are the cells, such as CAR-T cells engineered or not, the antibodies armed or not, and the smaller protein scaffolds that can be modified to render them specific of other proteins, à la façon of antibodies. For several years, we explored ways to substitute antibodies by nanobodies (also known as VHHs), the smallest recognizing part of camelids' heavy-chain antibodies: production of those small proteins in host microorganisms, minute analyses, characterization, and qualification of their affinity towards designed targets. Here, we present three standard VHHs described in the literature: anti-albumin, anti-EGF receptor and anti-HER2, a typical cancer cell surface -associated protein. Because they differ slightly in global structure, they are good models to assess our body of analytical methodologies. The VHHs were expressed in several bacteria strains in order to identify and overcome the bottlenecks to obtain homogeneous preparations of this protein. A large panel of biophysical tools, ranging from spectroscopy to mass spectrometry, was here combined to assess VHH structural features and the impact of the disulfide bond. The routes are now ready to move to more complex VHHs raised against specific targets in numerous areas including oncology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ab.2019.113491 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enzymatic, structural, and biophysical characterization of a single-domain antibody (VHH) selectively and tightly inhibiting neutrophil elastase and exhibiting favorable developability properties.
Protein Sci
December 2024
Nano-Antibodies to Explore Protein Structure and Functions (NEPTUNS), Centre for Protein Engineering, InBios, Department of Life Sciences, University of Liège, Liège, Belgium.
Human neutrophil elastase (hNE), a serine protease released by neutrophils during inflammation, plays a major role in the pathophysiology of several conditions especially in inflammatory lung diseases. Its inhibition constitutes, therefore, a promising therapeutic strategy to combat these diseases. In this work, we characterized the in vitro properties of a VHH (i.
View Article and Find Full Text PDFDistinct types of VHHs in Alpaca.
Front Immunol
November 2024
Drug Discovery and Development, Shanghai Cell Therapy Group Co. Ltd, Shanghai, China.
Introduction: VHHs (VH of heavy-chain-only antibodies) represent a unique alternative to Q7 conventional antibodies because of their smaller size, comparable binding affinity and biophysical properties.
Method: In this study, we systematically analyzed VHH NGS sequences from 22 Alpacas and structure data from public database.
Results: VHHs in Alpaca can be grouped into five main types with multiple distinct sequence and structure features.
Neutralizing VHH Antibodies Targeting the Spike Protein of PEDV.
Vet Sci
November 2024
Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals, Engineering Technology Research Center for Modern Animal Science and Novel Veterinary Pharmaceutic Development, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.
Porcine epidemic diarrhea virus (PEDV) is a highly contagious coronavirus that infect pigs' intestinal epithelial cells, causing high morbidity and mortality. Due to the rapid mutation of PEDV, vaccine efficacy is uncertain, prompting exploration of alternative treatments. Nanobodies, also known as variable heavy chain domains of heavy chain-only antibodies (VHHs), offer significant potential in biomedical applications due to their small size and high specificity.
View Article and Find Full Text PDF[High expression of variable domain of heavy-chain antibodies in Expi293F cells with optimized signal peptide and codons].
Sheng Wu Gong Cheng Xue Bao
November 2024
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730000, Gansu, China.
Article Synopsis
- The study focuses on improving the production of heavy-chain antibodies (VHH) for drug therapy and research by optimizing expression systems.
- The researchers identified an effective signal peptide (SP IFN-α2) that enhanced VHH secretion and implemented codon optimization to significantly increase yield while maintaining functional binding activity.
- The optimized process resulted in an average yield of over 191.6 mg/L for multiple VHHs, indicating a promising method for large-scale production in mammalian cells, particularly Expi293F cells.
Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion.
Front Oncol
October 2024
Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Background: Vγ9Vδ2 T-cells are antitumor immune effector cells that can detect metabolic dysregulation in cancer cells through phosphoantigen-induced conformational changes in the butyrophilin (BTN) 2A1/3A1 complex. In order to clinically exploit the anticancer properties of Vγ9Vδ2 T-cells, various approaches have been studied including phosphoantigen stimulation, agonistic BTN3A-specific antibodies, adoptive transfer of expanded Vγ9Vδ2 T-cells, and more recently bispecific antibodies. While Vγ9Vδ2 T-cells constitute a sizeable population, typically making up ~1-10% of the total T cell population, lower numbers have been observed with increasing age and in the context of disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!